
## Limbic encephalitis as a model of immune-mediated epilepsies: definition, etiology, electro-clinical features and outcome.

Morano A<sup>1</sup>, Casciato S<sup>1</sup>, Fattouch J<sup>1</sup>, Fanella M,<sup>1</sup> Albini M<sup>1</sup>, Di Gennaro G<sup>2</sup>, Quarato PP2, Mascia A<sup>2</sup>, D'Aniello A<sup>2</sup>, Giallonardo AT<sup>1</sup>, Di Bonaventura C<sup>1</sup>

<sup>1</sup> Epilepsy Unit, Department of Neurology and Psychiatry, "Sapienza" University, Rome, Italy <sup>2</sup> Epilepsy Surgery Unit, IRCCS NEUROMED Pozzilli (IS), Italy


**Purpose.** Limbic encephalitis (LE) is an overlooked, potentially treatable condition, typically characterized by the sub-acute onset of amnestic syndrome, psychiatric features (including behavioral/personality changes and mood disturbances) and seizures. The aim of our study is to describe and analyze the electro-clinical features, serological findings, neuroimaging characteristics and outcome of 22 LE patients in order to further understand this complex condition and improve its therapeutic strategies.

**Methods.** This is a retrospective cohort study including adult patients with electro-clinical features consistent with the diagnosis of "probable LE"<sup>1</sup>, identified between January 2010 and January 2015. Demographic data, seizure semiology, EEG pattern, MRI features, complete CSF and serum findings, therapeutic strategies were collected and reviewed.






| Table 1. Complete general findings in LE patients.  |                               |
|---|-------------------------------|
| History of recent infective/inflammatory disease<br>- Yes   | 5/22                          |
| <b>History of neoplasms</b><br>- Yes  | 4/22                          |
| Cognitive disturbances (Memory functions)<br>- Amnestic/Non-amnestic  | 19/22                         |
| Mood/behavioural changes<br>-Depressive disorder<br>-Agitation/delirium   | 7/22<br>5/22                  |
| <b>Type of seizures/paroxysmal movement disorders</b><br>- Focal seizures (with/without consciousness impairment)<br>- Facio-brachial dystonic seizures (FBDS)<br>- sTCGS<br>- Cluster seizures/NCPSE | 20/22<br>2/22<br>7/22<br>5/22 |
| Other signs/symptoms<br>-Sleep disorders<br>-Autonomic/sensorial alterations  | 8/22<br>2/22                  |
| <b>Ictal EEG (14/22)</b><br>- Unilateral<br>- Bitemporal/diffuse  | 5/14<br>9/14                  |
| <b>Laboratory findings</b><br>- Hyponatremia  | 7/22                          |
| <b>Disease duration at time of diagnosis/treatment</b><br>-1-2 months<br>-3-6 months  | 12/22<br>10/22                |
| <b>Disease course</b><br>- Monophasic<br>- Relapsing/Polyphasic   | 15/22<br>7/22                 |



**Results.** 22 patients (13 M, mean age 63 ys) were included in the study. All presented seizures at onset (17 complex partial, 5 simple partial, 2 FBDS); in 14 cases seizures were recorded (left temporal lobe onset in 4, right in 1, bitemporal in 9). 19 subjects had memory deficits; 12 presented behavioural/mood disorders; 8 suffered from sleep disorders and in 7 hyponatremia was documented. 5 individuals reported recent infections and 4 had a history of tumor. In 10/22 patients autoantibodies were detected (3 anti-VGKC/LGI-1, 4 VGKC/CASPR-2; 1 anti-NMDAR, 1 anti-SOX-1, 1 anti-Ri/Hu). In 20 subjects brain MRI at onset showed alterations involving mesial temporal lobes (bilaterally in 15 cases). All patients received immunomodulating treatment (10 iv/po steroids alone, 6 steroids+IVIG, 2 steroids+IVIG+plasma exchange). At follow-up, 7/22 patients had drugresistant epilepsy; memory deficits persisted in 13/22, psychiatric disturbances in 14/22 (Table 1 and Figure 2).





**Discussion.** Our work shows no significant differences in prognosis between "seronegative" and "seropositive" patients<sup>2</sup>. The bilateral involvement of mesial temporal structures is correlated with a worse outcome, especially in terms of memory/psychiatric disorders. Those patients with a definite "limbic syndrome" at onset achieve better seizure control, which may be partially explained by the prompt start of immunomodulation<sup>3</sup> (Figure 3).

**Conclusions.** Early recognition of LE and prompt immunomodulating therapy are of great importance to prevent the development of neurological sequelae, particularly cognitive impairment.



## 1. Bien CG, Elger CE. Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav 2007; 10: 529–38 2. Graus F et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology. 2008 Sep 16;71(12):930-6 3. Vincent A, Crino PB. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia. 2011 (b) May; 52 Suppl 3:12-7 4. Graus F et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr;15(4):391-404.